The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
This federal Project Grant award of $725,088 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to optimize the effectiveness and implementation of COPD self-management treatment. The primary goal is to conduct a factorial optimization trial among 448 individuals with COPD to evaluate the impacts of treatment components including self-management education, physical activity, and inhaler training on respiratory-related hospitalizations and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $117,750 to the Ann & Robert H Lurie Children's Hospital of Chicago to develop and validate the use of wireless biosensors and a portable capnograph device for remote patient monitoring of children on long-term invasive home mechanical ventilation. The project aims to address limitations of the hospital's current hand-collected vital sign data approach by...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will evaluate the use of mobile devices to extract vital signs to monitor patients with asthma. The $459,127 award to M5 Enterprise, LLC (doing business as Emedical Sentry) aims to improve the detection and management of asthma attacks through remote patient monitoring. The goal is to enhance telehealth by incorporating video-based vital sign...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $477,290 to Mayo Clinic to investigate the underlying behavioral mechanisms that impact a home-based pulmonary rehabilitation program for patients with chronic obstructive pulmonary disease (COPD). The research aims to determine the associations between patterns of physical activity, sedentary behavior, sleep, and cognitive...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
This $189,332 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to transform the delivery of interstitial lung disease (ILD) care through remote patient monitoring and artificial intelligence-powered clinical decision support. The key products and services to be delivered under this 5-year grant include: Identifying provider and health system barriers to adopting a remote patient monitoring...
This Project Grant award of $2,369,201, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to develop a population-based analytics and data infrastructure to evaluate the impact of non-COPD medications on outcomes for patients with Chronic Obstructive Pulmonary Disease (COPD). The overarching goal is to leverage existing claims data and electronic health records, including data from the COPDGene cohort study, to identify potential...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $300,000 to develop a hand-held smart sensor system that can noninvasively detect exhaled volatile organic compound (VOC) biomarkers for predicting pulmonary exacerbations in children with cystic fibrosis. The goal is to leverage machine learning to identify a breath-based biosignature for pulmonary exacerbations, design and test...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, aims to leverage quantitative imaging data from lung cancer screening to develop tools for detecting chronic obstructive pulmonary disease (COPD). The $626,247 award to the Regents of the University of Michigan will fund research to: 1) characterize COPD-related pathology from lung cancer screening CT scans, and 2) build a...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,107,276 to Lasarrus Clinic And Research Center Inc. to develop a mobile health system for remote monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD). The project aims to enhance patient adherence to remote monitoring and early symptom recognition, in order to reduce COPD readmissions and healthcare costs. The system utilizes a wearable multimodal sensor to capture physiologic baselines and changes in lung function, respiration, and activity in COPD patients. The project will validate the system through remote monitoring, usability, and adherence studies, with the goal of obtaining FDA 510(k) clearance and commercializing the solution through partnerships with Johns Hopkins, TidalHealth, and Tower Health.